By Lee Greenberger, Ph.D., LLS Chief Scientific Officer | April, 2021

The first big oncology meeting of the year, American Association for Cancer Research (AACR) kicked off with week one of the meeting held from April 10–15, 2021. Key topics from the virtual meeting include concerns for blood cancer patients such as building COVID-19 vaccine confidence and addressing cancer health disparities, as well as research into ways to improve CAR T-cell immunotherapy.

Read on for a closer look at the top news from AACR:

Building Vaccine Confidence

I was invited to speak on a panel called “Best Practices to Combat…


By Teri Johnson, Senior Vice President, Volunteer Engagement at LLS | April, 2021

When you commit time and talent to a nonprofit’s mission — no matter how you choose to get involved — you become a volunteer, and the impact of your efforts runs far deeper than the specific project or task you work on. For example, volunteers don’t always realize that the hours they spent stocking shelves meant hundreds of families would have food for two weeks. Or that the time spent fundraising not only raised critical mission dollars but also added value upward of $1,250 to the organization’s…


By Gwen Nichols, MD, LLS Chief Medical Officer | March, 2021

Here at The Leukemia & Lymphoma Society (LLS), we applaud every advance for children with blood cancers. Today’s reason to celebrate is the news that the U.S. Food and Drug Administration (FDA) expanded the approval of daunorubicin and cytarabine (Vyxeos®) to include treatment of pediatric patients aged one year and older with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). This is a welcome and necessary advancement in support of some of our most vulnerable patients.

The therapy was previously approved in 2017 for adult…


Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017. While all prior approvals with CAR T have directed the engineered T-cells to CD19, a marker on the surface of malignancies derived from B-cells, this is the first approval of a B-cell maturation antigen (BCMA)-directed CAR T. Idecabtegene vicleucel or ide-cel (Abecma) is the first approval of a CAR T for multiple myeloma. …


In honor of Myeloma Awareness Month in March, The Leukemia & Lymphoma Society (LLS) is shining a light on how we champion myeloma cures and care. For Jennifer Flowers, who was diagnosed with multiple myeloma in 2008, our free education and support services and the powerful sense of community at our Light The Night events have made all the difference. …


By Lee Greenberger, PhD, Chief Scientific Officer at LLS | March, 2021

The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.

LLS was among the first to invest in CAR T in the 1990’s. Today, the therapy has rapidly become a mainstay of cancer care. LLS supported clinical trials that lead to the first FDA-approvals in 2017 of tisagenlecleucel (Kymriah)…


The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, and Burlington Stores, the national retailer delivering amazing deals to customers every time they shop, teamed up for the 19th consecutive year to raise critical funds to support LLS’s goal of creating a world without blood cancer, and to furthering their LLS Children’s Initiative, a $100 million multi-year endeavor to help children not only survive, but thrive after treatment. …


Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancer, and what inspires their efforts to find better treatments and cures.

To commemorate Black History Month, LLS is highlighting exceptional clinicians and healthcare professionals throughout the month of February. Dr. Rayne Rouce is a physician at Texas Children’s Cancer Center where she is a member of the Leukemia/Lymphoma/Bone Marrow Transplant/Stem Cell Transplant Program. Dr. Rouce is board certified in pediatrics and pediatric hematology/oncology by the American Board of Pediatrics.

What is…


By Amanda Monteiro, LLS Volunteer & Children’s Initiative Ambassador

Amanda Monteiro is a leukemia mom, volunteer, and Children’s Initiative Ambassador for The Leukemia & Lymphoma Society (LLS), advocate for pediatric cancer research and palliative care, graduate student of clinical social work, and mother to Eleanor on earth and Edie in heaven.

Today is International Childhood Cancer Day, a day that had little significance for me less than four short years ago. In October 2017, I heard the words, “your child has cancer,” which I soon learned could only be eclipsed by, “there is nothing more we can do.”

I gave…


Approximately every three minutes — about the time it takes to read this article — someone in the U.S. is diagnosed with a blood cancer, including leukemia, lymphoma, or myeloma. And this year, leukemia, lymphoma, and myeloma will account for approximately 10 percent of all new cancer cases diagnosed in the U.S.

Every moment counts in the fight against cancer, and that’s why it’s so important to take action now. Patients and families are counting on us in their time of need, and during the pandemic, our help is even more critical. …

The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) is dedicated to funding research, finding cures and ensuring access to treatments for blood cancer patients.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store